Biotech IP Licensing ModelFree Financial Model Download
Value biotech licensing deals with realistic development timelines, milestone payments, royalty escalation, patent cliff exposure, and probability-adjusted cash flows from each clinical phase.
Free download. No sign-up required.
About this model
A biotech IP licensing model values a portfolio of royalties and development-stage assets by projecting risk-adjusted cash flows from a commercial out-licensed drug, multiple Phase III and Phase I assets, and platform R&D revenue. The model answers what the licensor should expect in annual earnings and cumulative NPV, accounting for patent cliff exposure (a 75% revenue drop when the commercial drug loses exclusivity), probability-of-success (PoS) adjustments on pre-commercial assets, and milestone payment timing tied to clinical and regulatory events.
The revenue structure combines three deal blocks: Deal A (commercial royalty, tiered 10–15% on partner net sales, losing exclusivity in year 6); Deal B (Phase III asset with milestone payments for Phase III readout, regulatory approval, and launch, plus PoS-weighted royalties); Deal C (Phase I asset with multiple development milestones and low cumulative PoS). Costs include third-party royalties payable on royalty revenue (1.5%), patent maintenance and legal ($4M base), R&D spending ($25M base, growing 6% annually), and G&A. The three-statement model projects EBITDA margins of 35–55% in pre-cliff years, declining to 10–20% in the cliff trough (years 6–8), recovering to 25–35% by year 10 as Deal B and Deal C contribute. A separate rNPV sheet shows unrisked and risked cash flows side-by-side for each deal, allowing investors to see the present value of each asset and understand concentration risk if a single deal fails.
Biotech investors, pharma acquirers, and royalty companies use licensing models to value IP assets, stress patent cliff downside by shortening LoE assumptions, and determine what acquisition price is justified for a portfolio of royalties and development optionality.
Recolor to your brand.
Formatted to IB standards.
Named theme colors repaint the whole workbook in one click, on top of an investment-banking structure with blue inputs, black formulas, and green cross-sheet links.
- Brand-ready
- Institutional grade
- Fully auditable
What's included
- Development probabilities by phase: preclinical through FDA approval
- Upfront and milestone payments tied to clinical and regulatory events
- Royalty rates by indication and volume with escalation and caps
- Peak sales forecasts with market penetration assumptions
- Risk-adjusted NPV with phase-appropriate discount rates
Built for licensing deal valuation
Use this model when probability-weighted milestone economics and royalty escalation drive the upfront vs. back-end deal structure decision.
Probability-weighted scenarios
A useful biotech model assigns realistic success probabilities at each phase and produces risked vs. unrisked NPV side-by-side.
Patent cliff aware
This explicitly tracks loss of exclusivity and the 80–90% revenue drop from generic entry rather than ignoring it.
Frequently asked
What is a biotech licensing model?+
It is a model that values out-licensed drug assets through probability-adjusted milestone payments, running royalties, and patent-life exclusivity.
What are typical success probabilities by phase?+
Phase 1: 65–75%, Phase 2: 30–50%, Phase 3: 25–35%, FDA approval: 85–90%. Combined preclinical-to-approval is often 5–10%.
How do I set royalty rates?+
Royalties are typically 3–10% of sales for small molecules and 5–15% for biologics, often escalating with sales volume or time.
How does patent expiration affect valuation?+
Generic entry typically reduces revenue 80–90%. The model captures the cliff and any exclusivity extensions.
Does it handle multiple indications?+
Yes. Model separate timelines, milestones, and royalty rates for each indication (oncology, cardiovascular, autoimmune).
Alex Tapio
Founder of Finamodel • Professional Financial Modeller • Ex-Deloitte
Related templates
Pharmaceutical Pipeline Valuation Model
Clinical trial progression, probability-weighted cash flows, and R&D project valuation for drug candidates.
Medical Device Financial Model
Revenue and profitability model for medical device companies including R&D, regulatory, manufacturing, and distribution.
Goodwill Impairment Testing Model
Annual impairment test model for purchased goodwill and intangibles under ASC 350, comparing fair value to book value.
Gym and Fitness Studio Operating Model
Operating model for fitness franchises and independent gyms including membership revenue, class scheduling, and facility utilization.